1	Supplementary data
T	Supplementary data

2

3

Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patients

- 7 8
- 9 The supplementary file includes 1 supplement with additional clinical methods.
- 10
- 11
- Tesa M. Severson^{1,2,3,*}, Yanyun Zhu^{1,2,*}, Stefan Prekovic^{1,2,*}, Karianne Schuurman¹, Holly M. Nguyen⁴, Lisha G.
 Brown⁴, Sini Hakkola⁵, Yongsoo Kim^{1,6}, Jeroen Kneppers^{1,2}, Simon Linder^{1,2}, Suzan Stelloo^{1,2,7}, Cor Lieftink³,
 Michiel van der Heijden^{3,8}, Matti Nykter⁵, Vincent van der Noort⁹, Joyce Sanders¹⁰, Ben Morris³, Guido Jenster¹¹, Geert JLH van Leenders¹², Mark Pomerantz¹³, Matthew L. Freedman^{13,14}, Roderick L. Beijersbergen⁶,
 Alfonso Urbanucci^{5,15}, Lodewyk Wessels^{2,3,16}, Eva Corey⁴, Wilbert Zwart^{1,2,17#}, Andries M. Bergman^{1,8#}
- 17
- 18 **1** Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, the Netherlands
- 19 2 Oncode Institute, the Netherlands
- 20 3 Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands
- 21 4 Department of Urology, University of Washington, Seattle, WA, USA
- 5 Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays
 Cancer Centre, Tampere, Finland
- 6 present working address: Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije
 Universiteit Amsterdam, Amsterdam, the Netherlands
- 26 7 present working address: Department of Molecular Biology, Faculty of Science, Radboud Institute for
- 27 Molecular Life Sciences, Oncode Institute, Radboud University Nijmegen, 6525 GA Nijmegen, The Netherlands.
- 28 8 Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands
- **9** Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
- 30 10 Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands
- 31 11 Department of Urology, Erasmus MC, Rotterdam, The Netherlands
- 32 12 Department of Pathology, Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, The33 Netherlands.
- **13** Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
- 35 14 The Eli and Edythe L. Broad Institute, Cambridge, MA, USA
- 36 15 Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
- **16** Department of EEMCS, Delft University of Technology, Delft, The Netherlands.
- 38 17 Laboratory of Chemical Biology and Institute for Complex Molecular Systems, Department of Biomedical
- 39 Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands.
- 40
- 41 *shared first authors
- 42 # corresponding authors: <u>w.zwart@nki.nl</u>, a.bergman@nki.nl

43 Supplementary Clinical Methods

44 Baseline characteristics and response data

In Supplementary Table 1, the baseline characteristics of all 64 included patients (whole 45 46 population) are summarized. Median age of the patients was 69 years and the majority of 47 patients had skeletal (75.0%) and/or lymph node (70.3%) metastases, while 34.4% had visceral organ metastases. Virtually all patients (93.8%) had PSA progression, while 48 radiographic progression was established in 81.3% of patients prior to enzalutamide 49 treatment. Approximately one-third of patients (32.8%) received enzalutamide as a first line 50 51 mCRPC treatment, while all other patients previously received other treatments, including docetaxel chemotherapy (62.5%) and the AR-signaling targeting agent abiraterone (23.4%). 52 Outcomes of treatment, after a median of 17 (IQR: 9-30) months follow-up, are summarized 53 54 in Supplementary Table 2. All patients in the trial were treated with enzalutamide (160 mg 55 once daily), except for one patient who was treated with abiraterone instead. The median duration of treatment was 22.7 (IQR: 13-45) weeks and 46.9% of patients had a \geq 50% 56 57 decrease of serum PSA from baseline. Complete or partial response was found in 18.8% of patients and 17.2% of patients had radiographic stable disease after 12 weeks of treatment. 58 The primary endpoint of the trial, Time to PSA progression (TTPP) was 17.7 (IQR 12-35) 59 weeks, while median overall survival was 14.5 months. 60

61

Rate of PSA response in the current study (enzalutamide-treated in first, second and later treatment lines) was lower than in the randomized controlled trial of first line enzalutamide (PREVAIL trial) (78%)¹, but in line with the randomized controlled trial of second line enzalutamide (AFFIRM trial) (54%)². The primary endpoint of the trial, Time to PSA progression (TTPP) was 17.7 (IQR 12-35) weeks which falls within the expected range considering 23.4% of patients in the current trial were previously treated with abiraterone and

2

68 consequently likely to have a lower likelihood of durable response due to cross-resistance³. However, the composition of patients in the trial, based on the line of treatment, deferred from 69 70 the assumption that 60% percent of patients would have been treated with enzalutamide as 71 a third or higher line of mCRPC treatment. This means that the trial population had fewer prior treatments than anticipated. The TTPP in the current trial was shorter than in the 72 AFFIRM trial (36 weeks)². Complete or partial response was found in 18.8% of patients and 73 74 17.2% of patients had radiographic stable disease after 12 weeks of treatment. Overall survival was 14.5 months which was shorter than the 18.4 months, reported in the AFFIRM 75 76 study².

77

In conclusion, enzalutamide treatment resulted in a TTPP within the expected range. The
TTPP was shorter than in the registration studies PREVAIL and AFFIRM, which is explained
by the miscellaneous population with more pretreatments, most notably prior abiraterone.

81

82 Trial procedure and patient outcomes

Baseline studies included radiographic evaluation (CT scan of thorax and abdomen), physical 83 examination, ECOG performance score, blood cell counts and serum chemistry and a biopsy 84 from a metastatic site. Subsequently, patients were treated with enzalutamide at a starting 85 dose of 160 mg/day (4 tablets of 40 mg once daily). Dose adjustments to as low as 80 mg/day 86 87 were allowed. During the course of enzalutamide treatment, physical examination, ECOG performance score, blood analysis, including PSA measurements, was performed every four 88 weeks at the outpatient clinic. A radiographic response was evaluated at 12 weeks by means 89 90 of a CT scan of thorax and abdomen (RECIST1.1). Patients with bone only metastases were considered progressive when new metastases were detected. In these patients, a response 91 92 to treatment could not be evaluated. Enzalutamide treatment was continued until progression or intolerance and selection of subsequent treatment. Frequency of visits to the outpatient clinic and assessments beyond enzalutamide treatment were at the discretion of the physician. Primary endpoint of the study is Time to PSA Progression (TTPP) defined as time from inclusion into the trial until date of a confirmed second PSA rise (PCWG3). Secondary recorded clinical outcomes are, rate of ≥50% serum PSA decrease from baseline, radiographic response (RECIST 1.1 criteria) and overall survival (OS) defined as time from inclusion into the trial until death.

100

101 Trial statistical analysis

102 For biomarker discovery purposes, we aimed to construct a cohort of enzalutamide treated 103 patients at various lines of mCRPC treatment in a Phase 2 clinical trial, which is 104 representative for the general population. The first line enzalutamide PREVAIL study¹ 105 showed an 11.2 month (48.7 weeks) time to PSA progression (TTPP), while the second line enzalutamide AFFIRM study² showed an 8.3 month (36.1 weeks) TTPP. A retrospective 106 107 study into enzalutamide treated patients in fourth or fifth line, suggested a TTPP of 3.6 months (15.7 weeks)⁴. We assumed to enroll 20% of patients treated with enzalutamide as a first line 108 109 treatment, 20% as a second and 60% of patients in a higher line of treatment. Consequently, 110 we expect a TTPP in this miscellaneous population of 22 weeks. Inclusion of 60 patients will 111 allow the detection of this median TTPP with 95% confidence intervals of 16.4-33.6 weeks. 112 This expected range is sufficiently narrow, that when the true TTPP falls within these limits, it suggests that results of the trial are representative and can be interpreted clinically. All time-113 to-event endpoints were estimated by the Kaplan-Meier method. Differences in normally 114 115 distributed baseline characteristics and study outcomes between the whole population and the evaluable pre-treatment biopsy and post-treatment biopsy sub populations were 116 117 evaluated by a student t-test.

4

118

131

5

- 119 Supplemental Methods References
- 1201Beer, T. M. *et al.* Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J121Med **371**, 424-433 (2014). https://doi.org:10.1056/NEJMoa1405095
- Scher, H. I. *et al.* Increased survival with enzalutamide in prostate cancer after chemotherapy.
 N Engl J Med 367, 1187-1197 (2012). <u>https://doi.org:10.1056/NEJMoa1207506</u>
- Khalaf, D. J. *et al.* Optimal sequencing of enzalutamide and abiraterone acetate plus
 prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised,
 open-label, phase 2, crossover trial. *Lancet Oncol* 20, 1730-1739 (2019).
 https://doi.org:10.1016/S1470-2045(19)30688-6
- 1284Badrising, S. K. *et al.* Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic129Castration-ResistantProstateCancer.Oncology91,267-273(2016).130https://doi.org:10.1159/000448219